Valneva SE (VLA.PA)
EUR 2.91
(0.62%)
EUR 2.91
(0.62%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -82.08 Million EUR | 8.25% |
| 2022 | -113.44 Million EUR | -84.79% |
| 2021 | -61.39 Million EUR | -11.4% |
| 2020 | -55.11 Million EUR | -3766.67% |
| 2019 | 1.5 Million EUR | -75.99% |
| 2018 | 6.26 Million EUR | 258.35% |
| 2017 | -3.95 Million EUR | 90.71% |
| 2016 | -42.56 Million EUR | -113.54% |
| 2015 | -19.93 Million EUR | 16.3% |
| 2014 | -23.81 Million EUR | -14.2% |
| 2013 | -20.85 Million EUR | -62.52% |
| 2012 | -12.83 Million EUR | -188.32% |
| 2011 | -4.45 Million EUR | 47.12% |
| 2010 | -8.41 Million EUR | -33.71% |
| 2009 | -6.29 Million EUR | -99.59% |
| 2008 | -3.15 Million EUR | 34.09% |
| 2007 | -4.78 Million EUR | -2065.16% |
| 2006 | -221 Thousand EUR | 84.55% |
| 2005 | -1.43 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -24.98 Million EUR | 15.65% |
| 2024 Q1 | -25.54 Million EUR | 13.14% |
| 2023 Q2 | -18.39 Million EUR | -10.97% |
| 2023 Q4 | -29.4 Million EUR | -32.38% |
| 2023 Q3 | -22.21 Million EUR | -20.78% |
| 2023 FY | -104.08 Million EUR | 8.25% |
| 2023 Q1 | -16.57 Million EUR | 70.59% |
| 2022 Q4 | -56.35 Million EUR | -160.39% |
| 2022 Q1 | -18.42 Million EUR | -110.45% |
| 2022 FY | -113.44 Million EUR | -84.79% |
| 2022 Q3 | 93.31 Million EUR | 170.7% |
| 2022 Q2 | -131.98 Million EUR | -616.47% |
| 2021 Q2 | -55.03 Million EUR | -76.74% |
| 2021 Q3 | -151.43 Million EUR | -175.16% |
| 2021 Q4 | 176.21 Million EUR | 216.37% |
| 2021 FY | -61.39 Million EUR | -11.4% |
| 2021 Q1 | -31.13 Million EUR | -1085.31% |
| 2020 Q4 | -2.62 Million EUR | 91.41% |
| 2020 Q3 | -30.56 Million EUR | -38.83% |
| 2020 Q2 | -22.01 Million EUR | -25118.18% |
| 2020 FY | -55.11 Million EUR | -3766.67% |
| 2020 Q1 | 88 Thousand EUR | -96.39% |
| 2019 Q4 | 2.43 Million EUR | 262.29% |
| 2019 Q1 | 6.2 Million EUR | 16.11% |
| 2019 Q2 | -7.95 Million EUR | -228.14% |
| 2019 Q3 | -1.5 Million EUR | 81.12% |
| 2019 FY | 1.5 Million EUR | -75.99% |
| 2018 Q1 | 3.2 Million EUR | 177.23% |
| 2018 FY | 6.26 Million EUR | 258.35% |
| 2018 Q4 | 5.34 Million EUR | 494.03% |
| 2018 Q3 | -1.35 Million EUR | -46.12% |
| 2018 Q2 | -928 Thousand EUR | -128.98% |
| 2017 Q1 | 476 Thousand EUR | 113.64% |
| 2017 FY | -3.95 Million EUR | 90.71% |
| 2017 Q4 | -4.14 Million EUR | -155.3% |
| 2017 Q3 | -1.62 Million EUR | -221.1% |
| 2017 Q2 | 1.34 Million EUR | 181.72% |
| 2016 Q1 | -2.72 Million EUR | -3.62% |
| 2016 FY | -42.56 Million EUR | -113.54% |
| 2016 Q4 | -3.49 Million EUR | 13.22% |
| 2016 Q3 | -4.02 Million EUR | 87.56% |
| 2016 Q2 | -32.33 Million EUR | -1088.31% |
| 2015 Q3 | -2.65 Million EUR | 69.47% |
| 2015 Q4 | -2.62 Million EUR | 1.06% |
| 2015 FY | -19.93 Million EUR | 16.3% |
| 2015 Q2 | -8.69 Million EUR | -45.81% |
| 2015 Q1 | -5.96 Million EUR | 39.48% |
| 2014 FY | -23.81 Million EUR | -14.2% |
| 2014 Q4 | -9.85 Million EUR | -228.7% |
| 2014 Q3 | -2.99 Million EUR | 33.71% |
| 2014 Q2 | -4.52 Million EUR | 29.9% |
| 2014 Q1 | -6.44 Million EUR | -82.28% |
| 2013 Q3 | -9.6 Million EUR | -91.3% |
| 2013 FY | -20.85 Million EUR | -62.52% |
| 2013 Q1 | -2.42 Million EUR | 32.2% |
| 2013 Q2 | -5.02 Million EUR | -107.18% |
| 2013 Q4 | -3.53 Million EUR | 63.17% |
| 2012 Q4 | -3.57 Million EUR | -48.28% |
| 2012 Q3 | -2.41 Million EUR | 0.0% |
| 2012 FY | -12.83 Million EUR | -188.32% |
| 2011 FY | -4.45 Million EUR | 47.12% |
| 2010 FY | -8.41 Million EUR | -33.71% |
| 2009 FY | -6.29 Million EUR | -99.59% |
| 2008 FY | -3.15 Million EUR | 34.09% |
| 2007 FY | -4.78 Million EUR | -2065.16% |
| 2006 FY | -221 Thousand EUR | 84.55% |
| 2005 FY | -1.43 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -2305.832% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 35.555% |
| Adocia SA | -17.62 Million EUR | -365.821% |
| Aelis Farma SA | -6.46 Million EUR | -1170.5% |
| Biophytis S.A. | -14.33 Million EUR | -472.713% |
| Advicenne S.A. | -6.45 Million EUR | -1171.287% |
| genOway Société anonyme | 2.06 Million EUR | 4074.588% |
| IntegraGen SA | -183.77 Thousand EUR | -44568.335% |
| Medesis Pharma S.A. | -4.22 Million EUR | -1840.893% |
| Neovacs S.A. | -6.9 Million EUR | -1088.367% |
| NFL Biosciences SA | -4.43 Million EUR | -1752.804% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -10447.815% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -2516.524% |
| Sensorion SA | -22.31 Million EUR | -267.928% |
| Theranexus Société Anonyme | -7.64 Million EUR | -973.92% |
| TME Pharma N.V. | -5.62 Million EUR | -1359.584% |
| Valbiotis SA | -7.16 Million EUR | -1046.466% |
| TheraVet SA | -2.17 Million EUR | -3673.926% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | -304.609% |
| DBV Technologies S.A. | -85.24 Million EUR | 3.706% |
| Genfit S.A. | -26.58 Million EUR | -208.83% |
| GeNeuro SA | -14.35 Million EUR | -471.744% |
| Innate Pharma S.A. | -12.66 Million EUR | -547.936% |
| Inventiva S.A. | -102.7 Million EUR | 20.078% |
| MaaT Pharma SA | -19.94 Million EUR | -311.608% |
| MedinCell S.A. | -20.97 Million EUR | -291.319% |
| Nanobiotix S.A. | -26.77 Million EUR | -206.535% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | -257.117% |
| Poxel S.A. | -28.76 Million EUR | -185.381% |
| GenSight Biologics S.A. | -29.69 Million EUR | -176.424% |
| Transgene SA | -30.01 Million EUR | -173.514% |